Neal Shore European Urology Supplements

Slides:

Advertisements

Similar presentations

Pascal Rischmann European Urology Supplements

Advertisements

The PSA Era is not Over for Prostate Cancer

The Origin of the Bone Scan as a Tumour Marker in Prostate Cancer

Prostate Cancer 2008: Challenges in Diagnosis and Management

Prostate Cancer: Highlights from 2006

Management of Acute and Chronic Retention in Men

Volume 54, Issue 4, Pages (October 2008)

Hormone Therapy for Prostate Cancer: Exploring Current Controversies

Who Benefits from Neoadjuvant or Adjuvant Hormone Therapy?

Prostate Cancer Epidemic in Sight?

Failure to Achieve Castration Levels in Patients Using Leuprolide Acetate in Locally Advanced Prostate Cancer Olav Erich Yri, Trine Bjoro, Sophie D.

Treatment of Advanced and Metastatic Renal Cancer: A Revolution?

Bladder Cancer: A Major Public Health Issue

Back to the Future: Introduction and Conclusions

What is New in Hormone Therapy for Prostate Cancer in 2007?

Intermittent Hormone Therapy: What Is Its Place in Clinical Practice?

Prostate Cancer Management: What Does the Future Hold?

Counselling the Prostate Cancer Patient

Laurent Boccon-Gibod European Urology Supplements

Prostate Cancer Epidemic in Sight?

The PSA Era is not Over for Prostate Cancer

The Origin of the Bone Scan as a Tumour Marker in Prostate Cancer

Current Status of Combined Radiation Therapy and Androgen Suppression in Locally Advanced Prostate Cancer: What Is the Way Forward? Michel Bolla European.

An Update of Current Practice in Hypospadias Surgery

Richard C. Harkaway European Urology Supplements

Volume 50, Issue 5, Pages (November 2006)

Optimising Hormone Therapy in Advanced Disease

Optimal Control of Testosterone: A Clinical Case-Based Approach of Modern Androgen- Deprivation Therapy Bertrand Tombal, Richard Berges European Urology.

The Importance of Testosterone Control in Prostate Cancer

Antonio Alcaraz, Pierre Teillac European Urology Supplements

Bone Health in Patients With Prostate Cancer: Monitoring and Diagnosis

Optimal Testosterone Control and Eligard®

Insights into the Relationships between Prostatic Disorders and Their Potential Impact on Future Urologic Practice Claus Roehrborn European Urology.

Intermittent Hormone Therapy: What Is Its Place in Clinical Practice?

Long-Term Hormonal Therapy: Who Would Benefit?

Sergio Bracarda European Urology Supplements

Challenges and Opportunities in Hormone-Resistant Prostate Cancer

Christian Stief European Urology Supplements

Bisphosphonates Can Prevent Skeletal Complications of Malignant Bone Disease from Prostate Cancer and Renal Cell Carcinoma Fred Saad European Urology.

New Trends in Managing the Prostate Cancer Patient

Improving Outcomes in Prostate Cancer: Time to Tackle Bone Disorders

A Multidisciplinary Team Approach for the Optimal Clinical Management of Metastatic Hormone-Refractory Prostate Cancer—Case Study John Fitzpatrick European.

Who Forms Stones and Why?

Prostate Cancer 2008: Challenges in Diagnosis and Management

Martin Michel, Jean de la Rosette European Urology Supplements

Role of Luteinising Hormone Releasing Hormone (LHRH) Agonists and Hormonal Treatment in the Management of Prostate Cancer P. Mongiat-Artus, P. Teillac

How Do New Data from Clinical Trials Allow Us to Optimise the Assessment and Treatment of Patients with Benign Prostatic Hyperplasia? Vincenzo Mirone

Richard Berges European Urology Supplements

Axel Heidenreich European Urology Supplements

Improving Flexibility and Quality of Life for Your Patients: A Must?

Profile of Silodosin European Urology Supplements

Bob Djavan European Urology Supplements

Highlighting Unmet Needs: Real Patients, Difficult Choices

The Increasing Responsibility of the Urologist in Maintaining Bone Health in Prostate Cancer Patients Kurt Miller European Urology Supplements Volume.

Prognostic Factors in Non–Muscle-Invasive Bladder Tumors

Beyond Skeletal-Related Events

Treatment Options in Prostate Cancer Once Primary Therapy Fails

Early Single-Instillation Chemotherapy Has No Real Benefit and Should Be Abandoned in Non–Muscle-Invasive Bladder Cancer Sten Holmäng European Urology.

Clinical Management of Patients Receiving Tyrosine Kinase Inhibitors for Advanced Renal Cell Carcinoma Jan Roigas European Urology Supplements Volume.

Joaquim Bellmunt European Urology Supplements

Hormone Therapy: Improving Therapy Decisions and Monitoring

The Impact of Premature Ejaculation on Partners and Relationships

Oncoforum Urology: Prostate Cancer 2008 at a Glance

Diagnosis and Management of Cryptorchidism

Epidemiology and Demographics of Prostatitis

New Research Findings on Clinical Benefits of Bisphosphonates in Patients With Advanced Prostate Cancer Noel W. Clarke European Urology Supplements

Jan Roigas European Urology Supplements

Axel Heidenreich European Urology Supplements

Appropriate Castration with Luteinising Hormone Releasing Hormone (LHRH) Agonists: What is the Optimal Level of Testosterone? B. Tombal European Urology.

Introduction European Urology Supplements

Presentation transcript:

Introducing Vantas: The First Once-Yearly Luteinising Hormone-Releasing Hormone Agonist Neal Shore European Urology Supplements Volume 9, Issue 8, Pages 701-705 (October 2010) DOI: 10.1016/j.eursup.2010.08.004 Copyright © 2010 European Association of Urology Terms and Conditions

Fig. 1 Two-dimensional structures of histrelin, goserelin and leuprolide. European Urology Supplements 2010 9, 701-705DOI: (10.1016/j.eursup.2010.08.004) Copyright © 2010 European Association of Urology Terms and Conditions

Fig. 2 Three-dimensional structures of histrelin, goserelin and leuprolide. European Urology Supplements 2010 9, 701-705DOI: (10.1016/j.eursup.2010.08.004) Copyright © 2010 European Association of Urology Terms and Conditions

Fig. 3 Pivotal phase 3 study design [3]. European Urology Supplements 2010 9, 701-705DOI: (10.1016/j.eursup.2010.08.004) Copyright © 2010 European Association of Urology Terms and Conditions

Fig. 4 Effect of the histrelin implant on median serum testosterone levels in patients with advanced prostate cancer [3]. European Urology Supplements 2010 9, 701-705DOI: (10.1016/j.eursup.2010.08.004) Copyright © 2010 European Association of Urology Terms and Conditions